We're raising our price target on Cardinal Health after another stellar quarter of profits
Cardinal Health (CAH) reported Q1 FY2027 revenue of $67.51B (+4% YoY) and adjusted EPS of $3.26 (+28% YoY), beating estimates. The company raised its full-year EPS guidance to $12.80-$13.00. Shares rose over 3% on the news. CEO Jason Hollar highlighted strong demand in the Pharmaceutical and Specialty Solutions segment. The company also repurchased $500M in stock. Analysts raised the price target to $300 from $265.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations for continued cash flow generation and potential further buybacks.
Market read
The earnings surprise and guidance lift are likely to push CAH higher in the short term and support the broader healthcare distribution sector.
What to watch
Potential headwinds in the Global Medical Products segment and higher petroleum costs could limit upside.
Background
Cardinal Health is a major U.S. drug distributor that recently announced a CVS contract renewal and a $500M share repurchase.
Ticker impact
Cardinal Health reported Q1 FY2027 earnings beat and raised full-year EPS guidance, prompting a >3% stock rise.
upward pressure as the market prices in the earnings beat and raised guidance
The company posted 28% YoY EPS growth, beat consensus, and lifted its FY EPS outlook, which historically moves the stock higher.
Market effects
Strong results may boost sentiment for healthcare distributors and pharma supply chain stocks.
U.S. healthcare sector likely sees modest gains.
Limited to U.S. markets; no direct global macro effect.
Counterpoint
The stock may be overbought after the rally; a pullback could occur if guidance is not met.
Key entities
- companyCardinal Health
U.S. healthcare distributor (ticker CAH).
- companyCVS Health
Pharmacy partner with renewed contract.
